Talk: Mr Jeremy DiCandilo
PEDMARK® (sodium thiosulfate injection): approved for reduction of risk of ototoxicity associated with cisplatin in pediatric population with localized, non-metastatic solid tumors
Mr Jeremy DiCandilo, Fennec Pharmaceuticals
- Journey of Pedmark: Initial research, followed by clinical studies until approval by FDA (September 2022) & EMA (June 2023)
- Impact of cisplatin induced ototoxicity: monitoring, long term impact, importance of testing & treatment
- Details of Pedmark: dosing, administration, safety & efficacy in clinical trials
About Mr Jeremy DiCandilo
Jeremy DiCandilo, Lead Medical Science Liaison at Fennec Pharmaceuticals, USA
Mr. Jeremy DiCandilo is the Lead Medical Science Liaison at Fennec Pharmaceuticals. He received a Bachelor of Science in Nursing from Temple University, trained at University of Pennsylvania, and has 20 years of oncology nursing experience. Since joining Fennec prior to the launch of Pedmark in the US, his efforts have focused on establishing Pedmark as the standard of care for ototoxicity at several centers key centers across the US as well as supporting ongoing clinical trials.
Satellite event of the 58th Inner Ear Biology Meeting